Gynecologic Cancers

Ohio State University

Ohio State University Tumor Boards

Questions discussed in this category

Is it safe and/or necessary to combine osimertinib and carboplatin/paclixel for a patient with stage IV EGFR mutated NSCLC and advanced ovarian carcinoma?

Certainly ovarian cancer will respond to carboplatin and paclitaxel and it sounds like a reasonable chemotherapy to give to a stage IV NSCLC, however ...

1 Answer available

Gynecologic Cancers

Ohio State University

Questions discussed in this category

Related Topics in Gynecologic Cancers